Services
Economic modelling
.png){kind=icon}
Economic models designed to support pricing strategy, and market access across global and local settings.
- Decision analytic models in Excel and R, including cost-effectiveness and budget impact models, tailored to global and local HTA requirements.
- Pricing analysis to support reimbursement strategy and market access planning across healthcare systems.
- Independent model validation, and technical audit to ensure transparency, robustness and readiness for scrutiny.
- Early economic modelling to support reimbursement planning, identify value drivers and assess commercial potential.
Other services include:
- Model validation
- Burden of illness analysis
Success Stories
Stay in touch
Subscribe to Symmetron and stay up to date with recent news and announcements.
Oops! Something went wrong while submitting the form.
8 Devonshire Square,
London, EC2M 4PL, UK
Validating comparisons of disease treatments in the absence of head-to-head trials
Validating comparisons of disease treatments in the absence of head-to-head trialsModelling survival after the clinical trials have ended
Modelling survival after the clinical trials have endedOvercoming limited evidence to gain reimbursement for a blockbuster oncology drug
Overcoming limited evidence to gain reimbursement for a blockbuster oncology drugEvaluating the cost-effectiveness of a diagnostic device
Evaluating the cost-effectiveness of a diagnostic deviceDeveloping a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UK
Developing a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UKEvaluating the cost-effectiveness of a medical device
Evaluating the cost-effectiveness of a medical deviceOvercoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments
Overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatmentsGaining reimbursement for a drug targeting a rare disease
Gaining reimbursement for a drug targeting a rare disease